Prolacta Bioscience® to Participate in Panel Addressing Clinical Quality and Safety of Exclusive Human Milk During National Coalition for Infant Health Policy Summit

News provided by

Oct 26, 2017, 08:05 ET

DUARTE, Calif., Oct. 26, 2017 /PRNewswire/ -- Prolacta Bioscience, the pioneer in human milk-based neonatal nutritional products for premature infants, will participate in the 2017 Infant Health Policy Summit, hosted by the National Coalition for Infant Health and the Institute for Patient Access, on Oct. 26, 2017, in Washington, D.C.

The Summit, titled "Diversity & Disparity: Breaking Down Access Barriers," provides a collaborative platform for health care providers, patient advocates, parents and policymakers to discuss patient access issues facing vulnerable premature infants and their families. The panel on "Milk Matters: Diversity, Quality & Safety," will include:

Dr. Mitchell Goldstein, Medical Director of the National Coalition for Infant Health, practicing neonatologist and Professor of Pediatrics at Loma Linda University;
Dr. Martha Dawson, Historian and Chair of the National Black Nurses Association Finance Committee and Assistant Professor and Coordinator of Nursing at the University of Alabama at Birmingham School of Nursing; and
Scott Eaker, Vice President of Quality and Regulatory Affairs at Prolacta Bioscience.

"The National Coalition for Infant Health's agenda is to make exclusive human milk the standard of care for all infants, and especially those born weighing less than 1,500 grams (3 pounds 5 ounces)," Goldstein said. "We are simultaneously raising awareness on this issue and working to ensure access to an exclusive human milk diet for low-income families through Medicaid reimbursement."

"Prolacta is proud to support the 2017 Infant Health Policy Summit, as we share a mutual commitment to making an exclusive human milk diet accessible to all vulnerable premature infants in the NICU," Eaker said.

Now in its third year, the Policy Summit also explores issues related to maternal nutrition; nutritional practices in the neonatal intensive care unit (NICU), including infant tube feeding safety; respiratory health; and the potential risk of Hepatitis C transmission. The annual event draws attendees including individual health care providers, congressional leaders and staff, representatives from national nursing and physician organizations and national and regional preemie parent organizations.

About Prolacta Bioscience
Prolacta Bioscience, Inc. is a privately-held life sciences company dedicated to Advancing the Science of Human Milk^®. The company pioneered the development of human milk-based neonatal nutritional products to meet the needs of critically ill, premature infants in the NICU. Prolacta leads the industry in the quality and safety of nutritional products made from donor breast milk and operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk.

www.prolacta.com

SOURCE Prolacta Bioscience